San Diego, CA—CV Sciences has published four papers in theJournal of Dietary Supplementsfirst special issue on cannabinoids, according to a press release.

Douglas MacKay, N.D., SVP of Scientific and Regulatory Affairs, co-edited the issue and co-wrote aneditorialoutlining the intent of the special issue, which is to address key scientific questions related to benefits, safety, and composition of hemp-derived CBD products, according to the press release.

Two CV Sciences employees—Osvaldo Marinotti, Ph.D., Senior Scientist, and Miles Sarill, M.Sc., National Educator—teamed up to writeDifferentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science. The paper says it “aims to provide clarity on differentiating botanical full-spectrum hemp extracts containing CBD from isolates, from a phytochemical, toxicological, and regulatory perspective.”
Related: Phytocannabinoids & the ECS: Your Top Qs, Answered! Selling Phytocannabinoids: 4 Success Secrets The Sleep-Stress Connection
The special issue also published two previously announced studies demonstrating the safety and health benefits of PlusCBD products:
  • Post Marketing Safety of PlusCBD Products, a Full Spectrum Hemp Extract: A 2-Year Experience confirms a low rate of adverse effects in millions of consumers taking PlusCBD products over a two-year period. The press release points out that there were no reports of liver toxicity, which has been found in studies using high doses of CBD as a prescription drug. Lead author Stephen Schmitz, MD, MPH and co-founder of Supplement Safety Solutions, stated, “This is the first longitudinal study of a CBD dietary supplement being used in real-world conditions. This study represents two years of data and daily product use from millions of consumers and demonstrates that CV Sciences’ products are safe and well tolerated.”
  • Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects used PlusCBD products to determine their benefits on stress resilience, perceived recovery, mood, affect, body composition, and clinical safety markers in healthy human subjects. Lead author Hector L. Lopez, M.D., CSCS, FAAPMR, FISSN, commented, “In a first of its kind study, participants taking PlusCBD products had significant improvement in HDL cholesterol compared to placebo, while improvements in measures of stress response, life pleasure, wellness and sleep were also observed. We also found an excellent safety profile, with no adverse signals in liver or other biomarkers of health in the group treated with PlusCBD products.”
Dr. MacKay commented in the press release: “These studies add to the growing evidence supporting the safety and benefits of hemp-derived CBD by tracking participant experience and health outcomes while taking CV Sciences’ proprietary CBD products. In 2018, CV Sciences achieved self-affirmed GRAS (Generally Recognized as Safe) status as a result of our extensive non-clinical testing program. Now, I am proud to say that CV Sciences is the only CBD company that has published toxicology studies, randomized, placebo-controlled clinical trials, and a systematic evaluation of post-market safety data of our products.”

Joseph Dowling, CV Sciences Chief Executive Officer, added: “Observations from the food, supplement and cosmetic industries suggest that consumers expect a responsible, transparent, and science backed industry, that is fully FDA regulated. We agree with consumers, and that’s why we continue to lead the industry in advancing CBD science and regulatory compliance. We are proud to contribute our team’s expertise to this important cannabinoid report in the Journal of Dietary Supplements. These efforts help develop a framework for an FDA regulated industry that consumers can trust.”
Related: CV Sciences Reports Q2 Results